Accolade, Inc.
Accolade, Inc., together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, … Read more
Accolade, Inc. (ACCD) - Total Liabilities
Latest total liabilities as of November 2024: $334.45 Million USD
Based on the latest financial reports, Accolade, Inc. (ACCD) has total liabilities worth $334.45 Million USD as of November 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Accolade, Inc. - Total Liabilities Trend (2018–2024)
This chart illustrates how Accolade, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Accolade, Inc. Competitors by Total Liabilities
The table below lists competitors of Accolade, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Lushang Property Co Ltd
SHG:600223
|
China | CN¥942.21 Million |
|
Jilin Forest
SHG:600189
|
China | CN¥2.91 Billion |
|
Metro AG vz. (Pref Shares)
XETRA:B4B3
|
Germany | €10.67 Billion |
|
Shanghai Koal Software Co Ltd
SHG:603232
|
China | CN¥232.68 Million |
|
Bravura Solutions Limited
PINK:BVSFF
|
USA | $86.26 Million |
|
IMMOFINANZ AG
VI:IIA
|
Austria | €5.19 Billion |
|
SFTCF
PINK:SFTCF
|
USA | $636.55 Million |
|
Alembic Pharmaceuticals Limited
NSE:APLLTD
|
India | ₹30.81 Billion |
Liability Composition Analysis (2018–2024)
This chart breaks down Accolade, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.63 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.52 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Accolade, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Accolade, Inc. (2018–2024)
The table below shows the annual total liabilities of Accolade, Inc. from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-02-29 | $342.69 Million | -20.17% |
| 2023-02-28 | $429.28 Million | -0.11% |
| 2022-02-28 | $429.74 Million | +407.59% |
| 2021-02-28 | $84.66 Million | -42.87% |
| 2020-02-29 | $148.19 Million | -50.00% |
| 2019-02-28 | $296.38 Million | +28.43% |
| 2018-02-28 | $230.78 Million | -- |